Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2010 |
| End Date: | December 2011 |
A Phase 1b Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
The purpose of this study is to establish the safety and optimal dose of orally administered
PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
We found this trial at
11
sites
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Click here to add this to my saved trials
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
Click here to add this to my saved trials
Stanford university Hospital and Clinics Throughout our history, we have pioneered medical advances that save...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials